ATFX Releases Q3 2025 Trader Magazine: Your Essential Guide to Global Markets in Uncertain Times
The issue opens with Martin Lam, ATFX's Chief Analyst of Asia Pacific, who explores how protectionism, inflation, and economic fragmentation are reshaping sentiment. He calls for flexible trading strategies as global alignments shift. Dr. Mohamed Nabawy, ATFX MENA Market Analyst, adds that renewed tariff tensions could slow the U.S. and Europe, increasing the risk of equity market corrections driven by inflation or retaliation.
Nick Twidale, Chief Market Analyst for Australia, provides an outlook on AUD/USD, discussing the Reserve Bank of Australia's recent policy pause and the Australian dollar's sensitivity to China's economic trajectory and the broader commodity cycle. He also highlights several short-term technical indicators that traders should monitor closely. On the European front, Gonzalo Cañete, ATFX's Global Chief Market Strategist, focuses on GBP/USD and EUR/JPY, pointing to a rise in volatility across European currencies. He explains how the UK's alignment with U.S. policy contrasts with the eurozone's economic softness, while Japan's monetary tightening could expose EUR/JPY to downside risk in the months ahead.
Jessica Lin, Global Market Analyst for Asia Pacific, highlights gold's upward momentum driven by safe-haven demand, with potential highs near $3,800 if uncertainty continues. She also sees silver gaining once industrial demand picks up. In energy, Gab Santos, Market Strategist in the Philippines, forecasts oil prices averaging $61 per barrel, citing rising supply and weakening demand as key pressure points.
Dean Chen, ATFX Guest Analyst analyses the yen's rise after Japan's policy shift, warning of export risks, while noting the yuan's relative stability amid China's slowdown. Diego Albuja, ATFX LATAM Market Analyst, highlights USD/MXN trends driven by rate divergence and nearshoring momentum. Lucas Nguyen, ATFX Market Analyst (Vietnam), offers a technical view on EUR/USD, suggesting a breakout could mark the next major macroeconomic shift.
The Q3 2025 edition of Trader Magazine reflects ATFX's continued commitment to delivering timely, actionable insights in a rapidly evolving market landscape. Covering global economic shifts and key market drivers, the issue equips traders with well-rounded perspectives that combine strategic analysis with technical context to support more informed and confident decision-making.
About ATFX
ATFX is a leading global fintech broker with a local presence in 24 locations and holds 9 licenses from regulatory authorities, including the UK's FCA, Australia's ASIC, Cyprus' CySEC, the UAE's SCA, Hong Kong SAR's SFC, South Africa's FSCA, Mauritius' FSC, Seychelles' FSA, and Cambodia's SERC. With a strong commitment to customer satisfaction, innovative technology, and strict regulatory compliance, ATFX delivers exceptional trading experiences to clients worldwide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
an hour ago
- Korea Herald
DISASTER MANAGEMENT & EMERGENCY RESPONSE LEADERS TO CONVENE AT SIDEX 2025
SINGAPORE, July 8, 2025 /PRNewswire/ -- The Asia-Pacific region, the world's most disaster-prone area, faces growing threats from climate change. Natural disasters are becoming more frequent and severe, highlighting the urgent need for enhanced global preparedness and response. In response, the inaugural Singapore-International Disaster & Emergency Management Expo (SIDEX) 2025, organised by COSEM (the co-operative of the Singapore Civil Defence Force) and supported by the Singapore Civil Defence Force, is a timely initiative that brings together experts to exchange professional knowledge in this field. SIDEX 2025 will present a carefully curated three-day Conference and Exhibition from 19 to 21 November 2025 at Singapore Expo Hall 3, combining knowledge sharing, collaboration and innovation. The Conference, aptly themed "Ready Today, Resilient Tomorrow", will focus on three sub-themes: (1) Civil Protection & Safety, (2) Emergency Preparedness & Response, and (3) Disaster Management & Humanitarian Response. Attendees can expect a compelling lineup of international keynote speakers and expert panels, featuring leaders from various global organisations. Our keynote speakers, Mr Jim Pauley, CEO of National Fire Protection Association and Dr Sabrina Cohen-Hatton KFSM, Chief Fire Officer in West Sussex Fire & Rescue Service, will present actionable strategies to enhance disaster management and emergency preparedness, offering both insights and inspiration. They will be joined by panelists and moderators from leading international organisations. Complementing the Conference, the SIDEX 2025 Exhibition will spotlight the latest technologies and services in disaster management and emergency response. Trade visitors can look forward to an extensive display of innovative products and solutions. With over 300 exhibitors, 600 conference delegates and thousands of trade visitors expected, SIDEX 2025 is the premier event that offers the opportunity to expand your network and be part of shaping the future of disaster management and emergency response. Register now at for SIDEX 2025! Held in conjunction with SIDEX 2025 is the 8 th Edition of the Singapore-Global Firefighters and Paramedics Challenge (SGFPC), a flagship event organised by the Singapore Civil Defence Force. Held at Singapore Expo Hall 4 on 20 and 21 November 2025, SGFPC brings together firefighters, rescuers and paramedics from around the world to compete in exciting scenario-based challenges that test their skills, strength and teamwork. This event attracts fire chiefs, disaster management leaders and emergency response professionals globally. Beyond the international competition, SGFPC also features public challenge segments that engages the Singapore Civil Defence Force's community partners – including schools, community first responders and company emergency response teams – making it not just a competition, but a celebration of resilience, emergency preparedness and collaboration.
Korea Herald
11 hours ago
- Korea Herald
Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma
Expanded indication makes SIR-Spheres ® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, Mass., July 7, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug Administration (FDA) approved SIR-Spheres ® Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma (HCC) in the United States. With this approval, SIR-Spheres ® is the only radioembolization therapy approved for the treatment of both metastatic colorectal cancer (mCRC) of the liver and HCC in the U.S. HCC is the most common form of liver cancer in adults in the U.S., according to the American Cancer Society. Radioembolization–commonly referred to as selective internal radiation therapy (SIRT)–with SIR-Spheres ® uses personalized dosimetry to deliver the optimal dose of radiation directly to tumors in patients with HCC. This approval gives clinicians expanded flexibility in selecting a liver-directed therapy that aligns with patient-specific needs and treatment goals. "The expanded indication makes SIR-Spheres ® the only Y-90 treatment approved in the U.S. for both HCC and mCRC," said Matt Schmidt, CEO of Sirtex. "This milestone reflects our ongoing commitment to delivering flexible, personalized therapies—with multiple dose options available daily—that empowers physicians to treat patients when and where it works best." This regulatory milestone is supported by results from the DOORwaY 90 study, a prospective, multicenter, open-label clinical trial evaluating the safety and efficacy of SIR-Spheres ® in treating HCC. The study enrolled 100 patients across 18 U.S. centers, with 65 patients included in the interim primary efficacy cohort. DOORwaY 90 met its prespecified co-primary endpoints, demonstrating a best overall response rate (ORR) of 98.5% as assessed by independent central review. All evaluable patients demonstrated a response, indicating a 100% local tumor control rate. Additionally, the median duration of response (DoR) exceeded 300 days. These findings highlight SIR-Spheres ® as a highly effective liver-directed therapy with a favorable safety profile. "This study moves the field of radioembolization forward with reproducible dosimetry outcomes and a strong safety profile linked to very positive clinical results," said Dr. Armeen Mahvash, Interventional Radiologist at MD Anderson Cancer Center and Co-Principal Investigator of the DOORwaY 90 Study. "This will give multidisciplinary care teams the confidence to recommend SIR-Spheres ® for HCC treatment." For more information and details on how to incorporate SIR-Spheres ® into your practice, please contact Sirtex at info-use@ About SIR-Spheres ® SIR-Spheres ® Y-90 resin microspheres are indicated for the local tumor control of unresectable hepatocellular carcinoma (HCC) in patients with no macrovascular invasion, Child-Pugh A cirrhosis, well-compensated liver function, and good performance status. They are also indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Caution: Federal (USA) law restricts this device for sale by or on the order of a physician. Consult the Instructions for Use ( for a complete listing of indications, contraindications, side effects, warnings and precautions. About Sirtex Sirtex Medical is a global healthcare company focused on advancing minimally invasive, liver-directed cancer and embolization therapies. With offices in the U.S., Australia, Europe, and Asia, Sirtex delivers innovative interventional oncology and embolization solutions to physicians and patients worldwide. The company's lead product, SIR-Spheres ® Y-90 resin microspheres, is now the only FDA approved product in the United States indicated for both the treatment of hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC). For more information, visit
Korea Herald
13 hours ago
- Korea Herald
CJ AI R&D Division to Launch Millstone CUE in August, a Game Changer in Content Creation
SEOUL, South Korea, July 7, 2025 /PRNewswire/ -- CJ Group will launch its AI-powered video solution, Millstone CUE, this August, offering comprehensive services from video search and editing to content generation. The initial release will focus on automatically detecting and blurring people and objects within videos, with additional features to follow. Millstone CUE integrates proprietary AI Blur and AI Remover technologies that automatically detect and either blur or seamlessly remove individuals, brand logos and filming equipment appearing in video footage. Moving beyond traditional manual editing, the system understands the full context of a video and processes it automatically. Extensive testing has confirmed it can reduce editing time by up to 91 percent. CJ ENM first deployed AI Blur in internal video production workflows, validating its accuracy and performance. It was used in YouTube content featuring K-pop group ZEROBASEONE and Mnet's WORLD OF STREET WOMAN FIGHTER, accelerating the delivery of polished, professional videos. Following the official launch, Millstone CUE will be available to creators, broadcasters and businesses, making advanced video editing tools more accessible across the content industry. Unlike existing services, Millstone CUE uses proprietary AI to identify and track people and objects without the need for reference images. It performs reliably across a variety of angles, lighting conditions and distances. Patent applications have been filed in both Korea and international markets. Creators often struggle to properly remove sensitive or unwanted content due to time and budget constraints, while videos featuring numerous individuals are widely and indiscriminately shared. The exposure of individuals' faces without consent poses serious risks of privacy violations, unauthorized use and even potential criminal misuse. Unwanted elements such as filming equipment can also detract from a video's overall quality and viewer experience. Millstone CUE offers a solution. It safeguards individual rights and automates repetitive, labor-intensive editing tasks through AI, allowing creators to focus on creative expression. The tool enables content production that is efficient, ethically responsible and delivers both speed and integrity in the creative process, including CG/VFX workflows. CJ Group sees Millstone CUE as a pivotal step toward a paradigm shift in how content is created. The company plans to enhance the platform with AI innovations across video search, editing and generation to elevate content quality and viewer engagement. "Millstone CUE marks the beginning of our journey to transform culture through AI," said CHihoon Lee, head of CJ's AI R&D Division. "Our AI technology acts as a creative collaborator and enabler, helping produce immersive, high-quality content. We are shaping the future of Korea-focused AI, building on our global technological strengths to lead the next wave of cultural innovation."
